+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "GLP-1 Receptor Agonist"

Antidiabetics Market Report 2026 - Product Thumbnail Image

Antidiabetics Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
From
Dulaglutide Market Report 2026 - Product Thumbnail Image

Dulaglutide Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
From
From
From
From
Diabetic Peripheral Neuropathy - Pipeline Insight, 2026 - Product Thumbnail Image

Diabetic Peripheral Neuropathy - Pipeline Insight, 2026

  • Clinical Trials
  • April 2026
  • 180 Pages
  • Global
From
Diabetes - Pipeline Insight, 2026 - Product Thumbnail Image

Diabetes - Pipeline Insight, 2026

  • Clinical Trials
  • April 2026
  • 450 Pages
  • Global
From
Type 2 Diabetes - Pipeline Insight, 2026 - Product Thumbnail Image

Type 2 Diabetes - Pipeline Insight, 2026

  • Drug Pipelines
  • April 2026
  • 280 Pages
  • Global
From
From
From
From
Type 2 Diabetes Market 2026-2030 - Product Thumbnail Image

Type 2 Diabetes Market 2026-2030

  • Report
  • April 2026
  • 305 Pages
  • Global
From
Non-Insulin Diabetes Therapeutics Market 2026-2030 - Product Thumbnail Image

Non-Insulin Diabetes Therapeutics Market 2026-2030

  • Report
  • January 2026
  • 286 Pages
  • Global
From
Insulin Resistance Epidemiology Forecast 2026-2035 - Product Thumbnail Image

Insulin Resistance Epidemiology Forecast 2026-2035

  • Report
  • May 2026
  • 150 Pages
  • Global
From
Loading Indicator

The GLP-1 Receptor Agonist market is a subset of the Central Nervous System Drugs market. GLP-1 Receptor Agonists are drugs that act on the GLP-1 receptor, a protein found in the brain and other parts of the body. These drugs are used to treat a variety of conditions, including obesity, type 2 diabetes, and depression. GLP-1 Receptor Agonists work by stimulating the release of insulin and other hormones, which can help regulate blood sugar levels and reduce appetite. GLP-1 Receptor Agonists are typically administered as injections, and are often used in combination with other medications. They are generally well-tolerated, with few side effects. However, they can be expensive, and may not be covered by insurance. Some companies in the GLP-1 Receptor Agonist market include Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi. Show Less Read more